ANDA 210726, held by Teva Pharms USA. Abiraterone Acetate.
As of Nov 15, 2026, ANDA 210726 (Abiraterone Acetate), held by Teva Pharms USA, was first approved by FDA on Jan 26, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 26, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Abiraterone Acetate500MG ยท tablet;oral | Abiraterone Acetate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
